I-Mab Logo
  • Investors
  • Careers
  • Contact
  • 简体中文
  • About
    • Story
    • People
    • Responsibilities
  • Innovation
    • Science
    • Capability
    • Publications
  • Pipeline
  • Partnerships
  • News
I-Mab Logo
  • About
    • Story
    • People
    • Responsibilities
  • Innovation
    • Science
    • Capability
    • Publications
  • Pipeline
  • Partnerships
  • News
  • Investors
  • Careers
  • Contact
  • 简体中文

Partner News

  • Press Releases
  • Media Reports
  • Partner News

2021.07.09

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

2021.06.29

NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

2020.11.09

Genexine and NeoImmuneTech Announce Data Release for their Phase 1/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-Negative Breast Cancer

2020.06.22

Genexine, “Hyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients”

Sitemap

  • Home
  • About
  • Innovation
  • Pipeline
  • Partnerships
  • News
  • Investors
  • Careers
  • Contact
  • 简体中文

Follow Us

  • LinkedIn
  • Twitter

Copyright © 2022 I-MAB Biopharma Co., Ltd. All Rights Reserved.

沪ICP备17007960号-2 | 沪公网安备31011502018701号